Search

Purpose: Positron emission tomography (PET) with the first and only tau targeting radiotracer of 18 F-flortaucipir approved by FDA has been increasingly used in depicting tau pathology deposition and distribution in patients with cognitive impairment. The goal of this international consensus is to help nuclear medicine practitioners procedurally perform 18 F-flortaucipir PET imaging., Method: A multidisciplinary task group formed by experts from various countries discussed and approved the consensus for 18 F-flortaucipir PET imaging in Alzheimer's disease (AD), focusing on clinical scenarios, patient preparation, and administered activities, as well as image acquisition, processing, interpretation, and reporting., Conclusion: This international consensus and practice guideline will help to promote the standardized use of 18 F-flortaucipir PET in patients with AD. It will become an international standard for this purpose in clinical practice., (© 2022. The Author(s).)

Purpose: Positron emission tomography (PET) with 18 F-fluorodeoxyglucose ([ 18 F]-FDG) has been increasingly applied in precise localization of epileptogenic focus in epilepsy patients, including pediatric patients. The aim of this international consensus is to provide the guideline and specific considerations for [ 18 F]-FDG PET in pediatric patients affected by epilepsy., Methods: An international, multidisciplinary task group is formed, and the guideline for brain [ 18 F]-FDG PET/CT in pediatric epilepsy patients has been discussed and approved, which include but not limited to the clinical indications, patient preparation, radiopharmaceuticals and administered activities, image acquisition, image processing, image interpretation, documentation and reporting, etc. CONCLUSION: This is the first international consensus and practice guideline for brain [ 18 F]-FDG PET/CT in pediatric epilepsy patients. It will be an international standard for this purpose in clinical practice., (© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.)

Purpose: To evaluate and compare diagnostic performance of 68 Ga-DOTA(0)-Tyr(3)-octreotate ( 68 Ga-DOTATATE) with 18 F-fluoro-2-deoxy-D-glucose ( 18 F-FDG) positron emission tomography-computed tomography (PET/CT) and anatomic imaging using computed tomography and/or magnetic resonance (CT/MR) imaging in detection of SDHx-related pheochromocytomas and paragangliomas (PPGLs) in pediatric patients., Methods: Nine pediatric patients (5:4, girls:boys; 14.6 ± 2.0 years) with an SDHx-related mutation (SDHB:SDHA:SDHD, n = 7:1:1) were included in this retrospective study. At the time of initial diagnosis, 7/9 patients had metastatic disease. They underwent CT/MR imaging along with PET/CT using 68 Ga-DOTATATE (n = 9), 18 F-FDG (n = 8), and positron emission tomography-magnetic resonance imaging (PET/MR) using 18 F-FDG (n = 1). In this manuscript, 18 F-FDG PET/CT refers to both 18 F-FDG PET/CT and 18 F-FDG PET/MR. The per-lesion, per-region, and per-patient detection rates were compared and calculated for each of the imaging modalities. A composite of all functional and anatomic imaging studies served as the imaging comparator., Results: Eight out of nine patients were positive for PPGLs on the imaging studies that demonstrated 107 lesions in 22 anatomic regions on the imaging comparator. The per-lesion detection rates for 68 Ga-DOTATATE PET/CT, 18 F-FDG PET/CT, and CT/MR imaging were 93.5% (95%CI, 87.0% to 97.3%); 79.4% (95%CI, 70.5% to 86.6%); and 73.8% (95%CI, 64.5% to 81.9%), respectively. The per-lesion detection rate for 68 Ga-DOTATATE PET/CT was significantly higher than that of 18 F-FDG PET/CT (p = 0.001) or CT/MR imaging (p < 0.001). In all of the anatomic regions except abdomen, the per-lesion detection rates for 68 Ga-DOTATATE PET/CT was found to be equal or superior to 18 F-FDG PET/CT, and CT/MR imaging. The per-region detection rate was 100% (95%CI, 84.6% to 100%) for 68 Ga-DOTATATE PET/CT and 90.9% (95%CI, 70.8% to 98.9%) for both 18 F-FDG PET/CT and CT/MR imaging. The per-patient detection rates for 68 Ga-DOTATATE PET/CT, 18 FDG PET/CT, and CT/MR imaging were all 100% (95%CI, 63.1% to 100%)., Conclusion: Our preliminary study demonstrates the superiority of 68 Ga-DOTATATE PET/CT in localization of SDHx-related PPGLs in pediatric population compared to 18 F-FDG PET/CT and CT/MR imaging with the exception of abdominal (excluding adrenal and liver) lesions, and suggests that it might be considered as a first-line imaging modality in pediatric patients with SDHx-related PPGLs.